(UroToday.com) Multiple gene expression signatures have been studied for their association with response to anti-PD1 axis therapy in metastatic renal cell carcinoma, but the utility of these signatures for predicting response to non-PD1 axis therapy is unknown. In this poster, Dr. Frede Donskov and colleagues explored the correlation of four specific gene expression signatures (T-cell inflamed gene expression profile [GEP], angiogenesis, monocytic myeloid-derived suppressor cells [mMDSC], and granulocytic myeloid-derived suppressor cells [gMDSC]) as well as PD-L2 single gene expression with response to targeted therapies.